Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report report published on Monday,Benzinga reports. The brokerage currently has a $18.00 price objective on the stock.

A number of other research firms have also weighed in on COYA. Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Lake Street Capital assumed coverage on Coya Therapeutics in a research report on Wednesday, July 9th. They issued a “buy” rating and a $16.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Wednesday, August 13th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Coya Therapeutics presently has a consensus rating of “Buy” and an average price target of $16.50.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $6.50 on Monday. The company has a 50-day moving average price of $6.05 and a 200-day moving average price of $6.08. The stock has a market capitalization of $108.75 million, a P/E ratio of -5.24 and a beta of 0.26. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.78 million. As a group, equities research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in Coya Therapeutics in the 4th quarter valued at about $74,000. Tower Research Capital LLC TRC increased its holdings in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after buying an additional 4,777 shares during the last quarter. Northern Trust Corp increased its holdings in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after buying an additional 3,099 shares during the last quarter. Geode Capital Management LLC increased its holdings in Coya Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock worth $863,000 after buying an additional 8,267 shares during the last quarter. Finally, DME Capital Management LP increased its holdings in Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after buying an additional 372,414 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.